CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells.Cells · 2025
   Review
2. Erythrocyte microRNAs show biomarker potential and implicate multiple sclerosis susceptibility genes.Clinical and translational medicine · 2020
   Article
3. Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis.BMC medical genomics · 2018
   Article
4. Immunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study.Frontiers in immunology · 2018
   Article
5. Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.Neurology · 2015
   Article
6. B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions.Frontiers in immunology · 2015
   Review
7. Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013
   Review
8. B cells and antibodies in multiple sclerosis pathogenesis and therapy.Nature reviews. Neurology · 2012
   Review
9. Erythrocytes in multiple sclerosis - forgotten contributors to the pathophysiology?Multiple sclerosis journal - experimental, translational and clinical
   Review

Corrections and comments

• Comment on
  CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.2010

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as